Why Some Patients Wait Months for Automated Insulin Delivery—and How to Avoid It

For many people living with diabetes, gaining access to an automated insulin delivery (AID) system can be life-changing. These technologies help improve glycemic outcomes, reduce hypoglycemia risk, and ease the daily burden of diabetes management. Yet despite their proven benefits, many patients continue to face lengthy delays before gaining access. Why does a therapy that can improve outcomes often take months to obtain?

Historically, the answer has involved insurance policies, documentation requirements, and administrative hurdles. However, the 2026 American Diabetes Association (ADA) Standards of Care signal a significant shift. The updated guidance emphasizes that access to diabetes technology should be based on clinical need rather than arbitrary laboratory thresholds. As a result, healthcare professionals now have stronger support when advocating for timely patient access.

Table of Contents

• Why AID Access Delays Continue
• What the 2026 ADA Standards Changed
• Strategies to Improve Automated Insulin Delivery Approvals
• Helping Patients Receive Technology Earlier
• Conclusion
• FAQs

Why Automated Insulin Delivery Access Delays Continue

Many insurance plans have historically required extensive documentation before approving an AID system. In some cases, patients were asked to complete C-peptide testing, diabetes autoantibody panels, or other laboratory evaluations before coverage decisions could be made.

These requirements often originated from older coverage policies that attempted to distinguish between diabetes types. However, diabetes management has evolved significantly. Today, clinicians recognize that insulin-requiring individuals may benefit from advanced technology regardless of whether they meet outdated biomarker criteria.

Consequently, approval timelines can become prolonged. Patients may wait weeks for laboratory appointments, additional weeks for results, and even longer for insurance reviews. Furthermore, missing documentation frequently triggers prior authorization denials, creating another layer of delay.

Clinical teams also face workflow challenges. Gathering records, responding to payer requests, and preparing appeals can consume substantial staff time. Therefore, even highly motivated practices may struggle to move approvals forward efficiently.

As AID technologies continue to demonstrate improved time in range and reduced glycemic variability, prolonged delays increasingly conflict with evidence-based diabetes care. The focus is shifting away from proving a diagnosis and toward identifying patients who can benefit clinically.

What the 2026 ADA Standards Changed

The 2026 ADA Standards of Care provide important support for broader technology access. Rather than emphasizing laboratory-based eligibility criteria, the updated recommendations focus on individual clinical needs and patient-centered decision-making.

This change reflects growing evidence that diabetes technology should not be restricted by outdated testing requirements. Instead, healthcare providers should evaluate whether an AID system can improve safety, glycemic management, and quality of life for a particular patient.

Importantly, the updated guidance can strengthen conversations with insurers. When coverage policies rely on older eligibility standards, clinicians may reference current ADA recommendations to support medical necessity arguments.

In addition, the revised standards encourage earlier technology adoption. Rather than waiting until glycemic control deteriorates, providers can consider AID systems proactively for appropriate patients. This approach aligns with preventive care principles and may help reduce future complications.

Healthcare professionals can review the latest standards through the American Diabetes Association publications and incorporate updated recommendations into clinical workflows.

Strategies to Improve Automated Insulin Delivery Approvals

Understanding eligibility requirements for automated insulin delivery systems remains essential, even as guidelines evolve. Although insurers may not immediately update policies, several practical approaches can help accelerate approvals.

First, letters of medical necessity should clearly document clinical need. Providers should explain how an AID system may improve glycemic outcomes, reduce hypoglycemia risk, or lessen disease burden. Specific examples often strengthen the request.

Second, clinicians should reference current guideline recommendations whenever appropriate. Citing updated ADA language can demonstrate that the request aligns with contemporary standards of care rather than outdated eligibility frameworks.

Third, practices should develop standardized documentation templates. Consistent workflows reduce errors and ensure required information is submitted from the start. As a result, fewer claims require resubmission or appeal.

Another effective strategy involves identifying payer-specific requirements early in the process. Different insurers may request different forms, clinical notes, or supporting documents. Therefore, verifying requirements before submission can prevent unnecessary delays.

Moreover, diabetes educators, pharmacists, and care coordinators can play a valuable role. Their involvement often improves communication between patients, providers, device manufacturers, and insurance representatives.

For practices seeking additional diabetes technology resources, educational content available through Diabetes In Control can support implementation efforts and patient education initiatives.

Helping Patients Receive Technology Earlier

Earlier access to AID systems may translate into better outcomes and greater patient satisfaction. Therefore, healthcare teams should actively identify candidates who may benefit from these technologies before complications or significant glycemic challenges emerge.

Patient education remains critical throughout the process. Individuals who understand expected timelines, documentation requirements, and potential insurance barriers are often better prepared to participate in the approval process.

Additionally, providers should encourage patients to maintain detailed glucose records and attend follow-up appointments. Comprehensive clinical documentation can support medical necessity claims and strengthen appeals when needed.

Some patients may also benefit from temporary assistance programs while insurance decisions are pending. Device manufacturers frequently offer support services designed to bridge access gaps and guide patients through the approval process.

When insurance denials occur, persistence matters. Many initial denials are overturned after additional clinical information is submitted. Therefore, practices should establish structured appeal protocols and continue advocating for eligible patients.

As eligibility standards for automated insulin delivery technologies become more aligned with clinical need, opportunities for earlier intervention are likely to expand. The challenge now is ensuring that administrative processes evolve as quickly as clinical evidence.

Conclusion

Delays in obtaining automated insulin delivery systems often stem from outdated insurance requirements, complex documentation demands, and administrative inefficiencies. However, the 2026 ADA Standards of Care provide stronger support for technology access based on clinical need rather than arbitrary laboratory thresholds. By leveraging updated guideline language, strengthening letters of medical necessity, and streamlining approval workflows, diabetes care teams can help patients gain access to life-changing technology more quickly and effectively.

FAQs

What determines eligibility for an automated insulin delivery system?

Eligibility for an automated insulin delivery system refers to the clinical and insurance criteria used to determine whether a patient qualifies for coverage and use of AID technology.

Why do insurance companies request C-peptide testing?

Historically, some insurers used C-peptide testing to classify diabetes type and determine technology coverage, although current guidelines increasingly support need-based access.

How do the 2026 ADA Standards affect AID approvals?

The updated standards emphasize clinical need rather than biomarker thresholds, providing stronger support for broader access to diabetes technology.

Can a patient appeal an AID system denial?

Yes. Many denials can be successfully appealed when additional clinical documentation and evidence-based rationale are provided.

Who benefits most from automated insulin delivery systems?

Individuals who use insulin and may improve glycemic control, reduce hypoglycemia risk, or decrease diabetes management burden can potentially benefit from AID technology.

Disclaimer: This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.